Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast Cancer
S. Bahnassy, H. Stires, L. Jin, S. Tam, D. Mobin, M. Balachandran, M. B. Podar, M. D. McCoy, R. A. Beckman, R. B. Riggins
The paper develops two in vitro models of endocrine therapy-resistant HER2+/ER+ breast cancer and identifies lipid metabolism and ferroptosis as therapeutic vulnerabilities.
bioRxiv · Aug 21, 2023Cancer Biology